L -arginine polymers inhibit the development of vein graft neointimal hyperplasia  by Kown, Murray H. et al.
D espite concerted efforts to increase the use of arter-ial grafts in recent years, saphenous veins remain
the most widely used bypass vessels in coronary artery
revascularization procedures.1 Unfortunately, venous
conduits develop accelerated atherosclerosis as a result
of neointimal hyperplasia. This is partially responsible
for the progressive occlusion that limits 15-year paten-
cies to approximately 50%.2
Vein graft injury initially results from increased wall
stresses incurred by arterial pressures, transient is-
Objective: We sought to determine whether L-arginine polymer treatment of
vein grafts enhances vascular production of nitric oxide and inhibits the
development of neointimal hyperplasia.
Methods: External jugular veins of New Zealand White rabbits (n = 42) were
harvested; treated intraluminally for 15 minutes with phosphate-buffered
saline solution or L-arginine polymer 5, 7, or 9 at either 10 or 100 µmol/L;
and then grafted into the contralateral carotid artery. Rabbits were killed
after 28 days, and 5-µm sections of vessels were stained with hematoxylin
and scored for intima/media ratio by using computerized morphometric
analysis. Separate veins were treated in a similar fashion with biotinylated
polymers and phosphate-buffered saline solution to assess for translocation
efficiencies. Finally, vein segments pretreated with either phosphate-
buffered saline solution or L-arginine polymers were cultured in Dulbecco’s
modified Eagle’s medium containing lipopolysaccharide (100 µg/mL) and
interferon γ (200 U/mL) for 48 hours before measuring nitric oxide levels by
means of the Griess reaction.
Results: Biotinylated L-arginine polymers demonstrated a dose- and length-
dependent uptake into intimal and medial cells of treated vessels. Nitric
oxide levels were significantly higher in vein segments treated with 100
µmol/L of L-arginine polymer 9 compared with control segments. Finally,
the intima/media ratio also reflected both length- and concentration-depen-
dent inhibition of neointimal hyperplasia.
Conclusions: Arginine polymers of sufficient length and concentration were
effective in increasing nitric oxide levels and reducing neointimal hyperpla-
sia in this vein graft model. (J Thorac Cardiovasc Surg 2001;121:971-80)
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Intima/media ratio
PBS R5 R7 R9
10 µmol/L 0.909 ± 0.072 0.920 ± 0.073 0.861 ± 0.138 0.710 ± 0.122
100 µmol/L 0.924 ± 0.061 0.581 ± 0.089* 0.529 ± 0.093*
PBS, Phosphate-buffered saline solution; R, L-arginine polymer.
*P < .001 versus phosphate-buffered saline solution and L-arginine polymer 5 controls (Bonferroni-
corrected value).
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chemia followed by reperfusion after grafting, and trau-
matic endothelial cell loss caused by manipulation.
These lead to the liberation of growth factors and
cytokines that influence the migration and proliferation
of vascular smooth muscle cells (VSMCs), as well as
the deposition of extracellular matrix into the intimal
compartment of the affected vessels.3
Nitric oxide (NO) is an important vasoactive mole-
cule that limits neointimal hyperplasia by inhibiting
VSMC proliferation and inducing cellular death by
apoptosis.4,5 It is a short-lived molecule that is formed
by the activity of nitric oxide synthase (NOS) on its
substrate, L-arginine. Although constitutive NOS is pre-
sent in endothelial and neuronal cells, a third isoform,
inducible NOS (iNOS), is expressed as a compensato-
ry mechanism in vascular injury.6 The synthesis of NO
during these periods of elevated iNOS appears to be
substrate limited,7 and indeed, numerous investigators
have used L-arginine administration to increase NO
production during conditions of vascular stress.8-10
It has recently been noted that short polymers of L-
arginine of 6 amino acids or greater in length are capa-
ble of translocating efficiently across cytoplasmic
membranes of vascular cells.11 Once located within the
cell, these polymers can provide the L-arginine sub-
strate for iNOS production of NO. The objective of this
study was thus to determine whether L-arginine poly-
mer treatment of vein grafts can enhance the produc-
tion of vascular NO and inhibit the ultimate develop-
ment of neointimal hyperplasia.
Methods
Peptide synthesis. Arginine polymers were synthesized on
an Applied Biosystems 433 peptide synthesizer by using pre-
viously described solid-phase techniques and commercially
available Fmoc amino acids, resins, and reagents (Applied
Biosystems, Foster City, Calif, and Bachem, Torrance, Calif).12
The following polymer sequences were used: L-arginine poly-
mer (R) 5, NH2-RRRRR-CONH2; R7, NH2-RRRRRRR-
CONH2; R9, NH2-RRRRRRRRR-CONH2; and phosphate-
buffered saline (PBS) solution. Biotinylated polymers of each
length were used in studies of translocation efficiency.
Animals. Male New Zealand White rabbits weighing
between 2.5 and 3.5 kg were purchased from Krelek Farms
(Stockton, Calif) and housed at the animal care facilities at
the Department of Cardiothoracic Surgery, Stanford
University Medical Center (Stanford, Calif). They were kept
Fig 1.  Representative figures of biotinylated L-arginine polymer and PBS-treated rabbit external jugular veins.
Vessel lumina are on the right side of each photomicrograph. Nuclei are visible as light green areas, whereas dark
brown regions signify areas of L-arginine polymer uptake. There is minimal biotin staining apparent in either PBS
or R5 groups in contrast to the darkened nuclei and cytoplasm of R7 and R9 categories. (Original magnification,
400×.)
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in rooms under normal temperature, humidity, and timed
lighting conditions and were provided standard food and
water ad libitum. Animals were treated in a humane manner
in compliance with the “Principles of Laboratory Animal
Care” formulated by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal
Resources, National Research Council, and published by the
National Academy Press, revised 1996.
Surgical procedure. After anesthesia with intramuscular
injection of 50 mg/kg ketamine and 5 mg/kg xylazine and mask
inhalation of 2.0% isoflurane, the external jugular vein was iso-
lated through a midline longitudinal neck incision. The vein
segment was flushed of blood with normal saline solution and
then instilled with either PBS, R5, R7, or R9 in solutions with
concentrations of 10 or 100 µmol/L for 15 minutes (n = 6 per
group). The segments were then reversed and anastomosed as
an interposition graft in an end-to-side fashion to the contralat-
eral carotid artery. The carotid artery segment between the prox-
imal and distal anastomoses was then ligated and transected.
Animals were killed after 28 days, and the vein grafts were per-
fusion fixed with 10% buffered formalin solution.
Translocating efficiency. To demonstrate the efficiency of
arginine polymer penetration of vascular cells in vivo, the
external jugular veins of New Zealand White rabbits were iso-
lated as above and incubated for 15 minutes with either PBS or
biotinylated R5, R7, or R9 in solutions of 10 or 100 µmol/L
concentrations (n = 1 per group). These were then flushed with
PBS solution before freezing in OCT compound and cutting
into 5-µm sections. Frozen sections were fixed in acetone for
10 minutes at –20°C, washed in PBS solution for 3 separate 5-
minute intervals, and incubated for 30 minutes with peroxidase
suppressor (Pierce Chemical Co, Rockford, Ill) to block
endogenous activity. Slides were then washed in PBS solution
as above and incubated with 5 µg/mL horseradish peroxidase-
conjugated streptavidin (Pierce Chemical Co) for 30 minutes.
They were then washed and incubated for 60 seconds with the
horseradish peroxidase substrate 3,3´-diaminobenzidine
(Sigma Chemical Company, St Louis, Mo). Reactions were
terminated by rinsing slides in distilled water before methyl
green counterstaining and dehydration in ethanol.
Because of the relatively thin media in native rabbit veins,
the same experiments were conducted in unused human saphe-
nous vein segments obtained from patients undergoing coro-
nary artery bypass grafting. The thicker vessel walls of the
human vein segments allowed better appreciation of medial
uptake. One vessel was treated per group, and 3 random high-
power fields per cross section were analyzed for translocation
of polymers. A quantitative measure of efficiency was calcu-
lated by dividing biotin-staining nuclei by total nuclei for both
Fig 2. Representative figures of biotinylated L-arginine polymer and PBS-treated human saphenous veins. As is the
case with rabbit veins, there appears to be little or no uptake of the polymers in either the PBS or R5 groups, where-
as considerable expression of biotin is noted in the intima and media of vessels in both the R7 and R9 groups.
(Original magnification, 400×.)
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intimal and medial regions of these vessels, and an average of
the 3 readings was taken. Statistical comparisons were made
between a group comprised of PBS and R5 categories (n = 3),
where little or no translocation was seen, and a group consist-
ing of R7 and R9 categories (n = 4), where high translocation
was present. The Medical Human Subjects Panel at Stanford
University approved the use of human tissues in this study.
NO assay. Efficacy of L-arginine polymer therapy was
assessed by means of in vitro assays for NO production.
Separate rabbit external jugular veins were sectioned and
treated with PBS solution or 100 µmol/L solutions of R5, R7,
or R9 for 15 minutes (n = 6 per group). The vein sections
were then incubated in Dulbecco’s modified Eagle’s medium
(Gibco BRL, Gaithersburg, Md) containing both lipopolysac-
charide (LPS; 100 µg/mL) and interferon (IFN) γ (200 U/mL;
Sigma Chemical Co) to upregulate iNOS production. After 48
hours’ incubation at 37°C, nitrite (NO2-) accumulation in the
cell culture medium was directly quantified by the Griess
reaction through a commercially available colorimetric assay
(Cayman Chemical, Ann Arbor, Mich). Values were mea-
sured as micromolar concentrations and standardized to the
weight of venous tissues in milligrams.
Vessel morphometry.  Finally, the biologic effect of L-
arginine polymer therapy was assessed by measuring the
degree of neointimal hyperplasia in the 28-day treated and
control vein grafts. The vein segments were placed in paraf-
fin blocks, and the middle portion of each specimen was cut
into 5-µm sections for staining with hematoxylin dye. A com-
puterized morphometric analysis program (C-Imaging
Systems, Cranberry Township, NJ) was used to measure inti-
mal and medial areas of one section per graft in a blinded
fashion. Neointimal hyperplasia is expressed as a ratio of
these two measures (intima/media ratio [I/M]).
Statistical analysis. Values are expressed as means ± 1 SD.
All comparisons were made by 1-way analysis of variance
(ANOVA; SYSTAT Inc, Chicago, Ill). Unpaired Student t tests
were used to identify statistical significance between groups,
with the Bonferroni correction for multiple comparisons.
Fig 3. Quantitative measure of translocation efficiencies on the basis of the number of biotin-staining nuclei
(brown) divided by the number of total nuclei (brown plus green) in human saphenous vein samples. Each bar rep-
resents the average of 3 random high-power field readings of a cross-section of a single vessel. One hundred micro-
molar concentration appears to translocate with the highest efficiencies. Average translocation of the PBS and R5
group was significantly lower than that of R7 and R9 (P < .001, Student t test).
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Results
Arginine polymer uptake efficiencies. Microscopic
examination of rabbit jugular veins treated with biotiny-
lated L-arginine polymers and PBS solution did reveal
length-dependent uptake. Although R7- and R9-treated
specimens exhibited evidence of vascular cell penetra-
tion to the level of the adventitia, neither the PBS nor
R5 groups showed appreciable staining (Fig 1).
Translocation efficiencies were estimated in human
saphenous vein segments because of the thicker medi-
al layer allowing a more detailed analysis of uptake
(Figs 2 and 3). R7 and R9 concentrations of 100
µmol/L resulted in the highest efficiencies at 81% and
86%, respectively. The intimal regions had greater
uptake than their medial counterparts because of their
direct exposure to treatment solutions. Neither PBS nor
100 µmol/L R5 groups had appreciable translocations.
Average intimal translocation efficiencies were 6% ±
3% for the PBS and R5 groups versus 73% ± 12% for
the R7 and R9 categories (P < .001, Student t test).
Measure of NO production. The effects of L-arginine
polymers on venous production of NO were measured in
vitro. Cytokine (IFN-γ) and endotoxin (LPS) stimulation
were used to upregulate iNOS levels13 in vein segments
pretreated with either PBS solution or L-arginine poly-
mers. Direct measurement of culture medium for the NO
byproduct, nitrite (NO2-), revealed a length-dependent
effect of the polymers at 48 hours with the R9 group hav-
ing the highest levels (P = .024, ANOVA; Fig 4). There
was also an incremental, although statistically insignifi-
cant, increase in NO in the R7-treated group when com-
pared with either PBS or R5 solution.
Measure of neointimal hypertrophy. All animals
survived until the time of harvest, at which point 88%
of the grafts were noted to be patent by means of direct
examination. There was no preponderance of early
occlusion in any of the study groups. Although each
vessel did have a degree of concentric neointimal
hyperplasia (Fig 5, A and B), I/M ratios, as measured
by means of computerized morphometric analysis, did
demonstrate a protective effect of L-arginine polymers
of sufficient length and concentration. One-way
ANOVA yielded a highly significant difference among
groups (P < .001). The I/M ratio in the PBS (0.91) and
Fig 4. NO production as measured by nitrite (NO2-) levels. Pretreated venous segments are incubated in culture
medium containing LPS (100 µg/mL) and IFN-γ (200 µg/mL) for 48 hours. Nitrite levels are measured directly
from culture medium by means of Griess reaction and standardized to weights of venous segments. There is a
length-dependent increase in nitrite levels with L-arginine polymer treatment. *P = .033 versus R5 100 µmol/L and
P = .085 versus PBS (Bonferonni-corrected value).
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both R5 groups (10 µmol/L R5, 0.92; 100 µmol/L R5,
0.92) were relatively consistent. A minimal reduction
in neointimal hyperplasia was seen at the lowest con-
centration of R7 (I/M, 0.86); however, it was not statis-
tically significant compared with that of the PBS group.
Concentration appeared to play a more important role
in efficacy of treatment in that 100 µmol/L R7 had a
greater effect on I/M than 10 µmol/L of the R9 solu-
tion. Finally, the greatest effect on I/M was seen with
the highest concentration and longest polymer length at
100 µmol/L R9. At 0.53, this group had an approxi-
mately 42% lower I/M ratio than the PBS or R5 control
groups (Fig 6).
Discussion
Autologous vein remains one of the most useful con-
duits for revascularization of arterial occlusive disease.9
Unfortunately, the development of neointimal hyperpla-
sia in these vein grafts is nearly universal and signifi-
cantly limits their long-term patencies. In this study we
found that the ex vivo treatment of vein graft segments
with L-arginine polymers upregulates their production
of NO and limits the development of neointimal hyper-
plasia in a length- and dose-dependent manner.
Previous reports have described various techniques
of manipulating NO production by vascular tissues.
These include gene transfer of endothelial NOS14 or
Fig 5. A, Low-magnification view (100×) of the concentric nature of neointimal hyperplasia visible at 28 days in
vein grafts stained with hematoxylin. Arrows delineate the neointimal layer. B, Higher magnification view (400×)
of low, medium, and high degrees of neointimal hyperplasia. Arrows depict the border between medial and neoin-
timal layers.
A
B
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iNOS,15 the regulation of intracellular cyclic adenosine
monophosphate in combination with proinflammatory
cytokines,16 and the dietary administration of the NOS
substrate L-arginine.17
Dietary L-arginine reduces monocyte adhesion to
vascular endothelium18 and is thought to mediate its
effects by increasing production of NO by these infil-
trating cells.19 The limitation of this mode of therapy,
however, is the transient nature with which plasma L-
arginine levels appear to be manipulated by dietary
supplementation. Jeremy, McCarron, and Sullivan19
found that despite continued oral administration of L-
arginine, plasma levels remained elevated only up to
14 weeks. This was apparently caused by modifica-
tion of L-arginine homeostasis either through
increased metabolism by arginase20 or enhanced uri-
nary excretion.21 The unsustainable elevations in plas-
ma L-arginine content also correlated with a lack of a
long-term benefit on vein graft endothelium-depen-
dent vasodilatation in their model.
We have shown that single-dose therapy with L-argi-
nine polymers of sufficient length and concentration
inhibited the development of vein graft neointimal
hyperplasia in an in vivo model. Sustained efficacy of
other single-dose treatments has been noted previously.
For example, ex vivo one-shot therapy with the NO
donor S-nitroso-N-acetylpenicillamine successfully
limited vein bypass neointimal formation in another
study.8 It appears that certain treatments centered
around the time of vessel perturbation with bypass
grafting are able to influence cell migration, matrix
production, and other variables associated with vascu-
lar remodeling, such that there are long-term inhibitory
effects on neointima formation.22
Histologic examination of the human vein grafts treat-
ed with biotinylated L-arginine polymers demonstrated
that there is considerable uptake deep into the vessel
wall at appropriate lengths and concentrations. Similar
ability for membrane translocation was also seen with
the Tat protein of the HIV-1 virus, which is rich in argi-
Fig 6.  I/M ratio of treatment and control groups of 28-day-old vein interposition grafts. I/M is lowest in both 100
µmol/L concentrations of R7 and R9. *P < .001 verus PBS, R5 10 µmol/L, and R5 100 µmol/L (Bonferonni-correct-
ed value).
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nine sequences (residues 49-57; RKKRRQRRR).23,24
Uemura and associates25 found that this process of poly-
arginine uptake appears to occur in vitro through an
energy-dependent mechanism (incubation with azide
abolishes uptake) and independent of the normal amino
acid transporter mechanisms. Incubation with excess
concentrations of L-arginine monomers failed to have
any appreciable effect on polymer uptake. If the poly-
mers did gain access to the cell through the same trans-
port mechanisms as the amino acid monomer, one might
expect competitive inhibition at these levels.
Once within the cell, arginine polymers can supply
the substrate for iNOS. This inducible form of NOS is
upregulated within smooth muscle cells of vessels sub-
jected to either endothelial injury26 or proinflammatory
cytokine stimulation.27 Measurement of nitrite in our
stimulated vein segments did demonstrate a length-
dependent upregulation of the molecule that may be
indicative of NO production by our treated venous
grafts. These in vitro results were modest, however, and
it is not known how long increases in NO would persist
in treated arterialized vein segments.
The ultimate effect of L-arginine polymers on neoin-
timal hyperplasia in vivo appears to be related to both
the amount of substrate provided, as well as their abil-
ity to gain access to the cell. Neither concentration of
R5 demonstrated any biologic effect on vein graft dis-
ease over PBS controls, and this is consistent with their
lack of uptake. Interestingly, R7 at a concentration of
10 µmol/L, while having fairly efficient intracellular
access, did not have any appreciable effect on the
development of increased I/M ratio at 28 days. This
suggests that although translocation is achieved, the
ultimate effect on vein graft atherosclerosis also relies
on the total substrate delivered to iNOS by the poly-
mers. Indeed, the greatest effect on I/M is achieved
with the maximum dose of 100 µmol/L and the longest
length of R9, respectively.
NO is an extremely diverse molecule, and focusing
only on its effects on VSMC proliferation may be over-
ly simplistic. The upregulation of iNOS under condi-
tions of endothelial damage may represent a unique
response to injury protective mechanism for vessels
subjected to various stresses. For example, NO-mediat-
ed vasodilatation and inhibition of platelet aggregation
may be an attempt by an injured vessel to stave off
early vein graft thrombosis.28 Other investigators have
demonstrated a protective role of exogenous NO deliv-
ery to hearts subjected to ischemia-reperfusion in-
jury.29,30 Future directions of study will look at the
effects of L-arginine polymer therapy in these important
areas and further delineate the unique roles of NO in
vascular graft biology.
Finally, arginine polymers may have intrinsic bene-
fits independent of their effects on NO synthesis. As the
photomicrographs depicting the biotinylated polypep-
tides suggest, R7 and R9 are capable of efficiently
translocating deep into vessel walls. By linking the
polymers to specific therapeutic agents, they may thus
have a distinct utility as a carrier protein for directed
treatments of various cardiovascular diseases.
Conclusion
In conclusion, L-arginine polymers of sufficient
length and concentration can efficiently translocate
across membranes of vascular cells in ex vivo treated
vein grafts. By providing the substrate for iNOS pro-
duction of NO, these constructs represent a novel ther-
apy for the inhibition of neointimal hyperplasia, which
may currently limit the long-term patency of venous
bypass grafts.
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Discussion
Dr Robbin Cohen (Los Angeles, Calif). Saphenous vein
grafts continue to be the most common conduits used by cardiac
surgeons for coronary artery bypass grafting. They are usually
readily available, can be removed endoscopically with minimal
morbidity, and have excellent and immediate flow characteris-
tics. Unfortunately, despite a tendency to become functionally
arterialized, a term I learned from Craig Miller, they tend to
respond to being interposed into the coronary arterial circula-
tion with neointimal hyperplasia, usually followed by accelerat-
ed atherosclerosis and premature occlusion.
You and your colleagues in Dr Robbins’ laboratory are to
be commended for tackling the huge problem of vein graft
failure to make the results of our most commonly used con-
duit more long lasting. Your ideal scenario goes something
like this: vein grafts that are rendered ischemic and damaged
by their excision react by producing iNOS. An easily admin-
istered single-dose bath of L-arginine in the appropriate size
polymers at the time of excision readily crosses the cell mem-
branes of vascular cells and serves as a substrate for NOS,
and the result is the production of NO, which fights off the
proliferation of VSMCs, thereby inhibiting neointimal hyper-
plasia and presumably preventing the development of vein
graft atherosclerosis. The study does provide potentially
important data, which suggest that certain lengths of L-argi-
nine polymers are taken up by vascular cells in a dose-depen-
dent fashion. This is followed by an increase in NO produc-
tion at 48 hours and a possible reduction in neointimal
hypertrophy at 28 days, as measured with the I/M ratio. What
the study does not do is justify your title. Although certainly
a precursor, neointimal hyperplasia is not synonymous with
atherosclerosis, nor was true atherosclerosis measured,
observed, or really even mentioned in your article. Whereas
your data warrant further investigation regarding the utility of
bathing freshly harvested vein grafts in L-arginine, the
assumption that it prevents atherosclerosis with the obvious
benefits is premature. Still, your data are valuable, and I have
3 questions.
In your article there is about a 12% early occlusion rate of
your vein grafts, which is not that dissimilar from what we
see clinically. Did you look at those occluded grafts in a sim-
ilar fashion to determine whether they produced increased
NO, and what was their neointimal hyperplasia situation like?
Dr Kown. Thank you for your comments, Dr Cohen.
Those 12% that were determined to be occluded were deter-
trying to extrapolate how much actual vein graft disease
occurs over the long term. The use of other models and time
points would be a natural extension of these studies, but we
believed that it was valuable to start with a snapshot of a sin-
gle time point.
Dr Charles Brantigan (Denver, Colo). I would like to
continue from where the previous discussant left off. Dr
Cohen talked about providing arginine to eliminate the
neointimal hyperplasia, and you talked about bathing the
vein grafts in L-arginine or maybe flipping an on-and-off
switch by presenting the bypass conduit with the L-arginine.
How about a strategy that involves bathing the vein graft in
arginine during the postoperative period by providing oral
arginine to the animal or to the patient? There has been
some evidence that suggests that giving L-arginine, which is
available from a health food store, will in fact increase the
levels of NO. We know that increasing the levels of NO
decreases neointimal hyperplasia. Why not just provide
something that is natural and free of side effects and thus
provide some protection on a long-term basis? Have you
investigated that strategy?
Dr Kown. We have seen from the literature that one way
to upregulate NO is to provide dietary L-arginine. In one
study with a hypercholesterolemic rabbit model, however,
the authors found that for some reason, with oral adminis-
tration of L-arginine, plasma levels were not maintained
past 14 weeks. They attributed this to some sort of com-
pensatory mechanism on arginine homeostasis by the body
that led to increased urinary excretion and increased
metabolism by arginase (which is the enzyme that will
metabolize L-arginine). They thus found that they did not
have a prolonged biologic effect past 14 weeks in that par-
ticular model.
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mined at the 28-day time point, well beyond the 48 hours that
we used in our assays for NO production. It appears that these
vessels were occluded because of early technical failure and
not excessive neointimal hyperplasia in that histologic exam-
ination revealed only fibrous strands of scar tissue, with no
evidence of any components of a vascular wall.
Dr Cohen. To perform your NO assay, you incubated vein
sections in substances that are designed to upregulate iNOS
production. Because your study makes ample L-arginine
available to the vascular cell, to what extent is it actually
dependent on that production of the iNOS? In other words,
how reliable is that production? How much damage and
ischemia has to occur for the production of NOS to occur, and
how will that affect the production of NO down the line?
Dr Kown. There are 3 isoforms of NOS. One is the consti-
tutive endothelial NOS, which is present in normal physio-
logic levels. If you did not have vessel perturbation associat-
ed with grafting, you would get a certain amount of NO
produced by the vessel just by virtue of the fact that the
endothelial NOS is present. This is easily discerned from how
much production is created by a stressed vessel by adding a
calcium ionophore because endogenous NOS is stimulated by
calcium levels. When you do that, you see a slight incremen-
tal effect of NO produced by vein grafts; however, the pre-
dominant effect seen in our model when you have stressed
vessels was from iNOS.
Dr Cohen. Finally, you chose as a single point in time, 28
days, to measure the I/M ratio and hence the degree of neointi-
mal hyperplasia. Why not multiple time periods? Is this ratio on
its way up or is it on its way down? Is this a long-lasting effect?
Why did you not look at it a little bit more carefully?
Dr Kown. I think that is a good question. By studying our
vein samples at 28 days for neointimal hyperplasia, we were
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